Redhill Biopharma Stock Performance
| RDHL Stock | USD 6.74 0.34 5.31% |
The company holds a Beta of 0.29, which implies not very significant fluctuations relative to the market. As returns on the market increase, Redhill Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Redhill Biopharma is expected to be smaller as well. At this point, Redhill Biopharma has a negative expected return of -0.24%. Please make sure to check Redhill Biopharma's skewness, and the relationship between the treynor ratio and rate of daily change , to decide if Redhill Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Redhill Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 2.78 | Five Day Return (5.67) | Year To Date Return (81.78) | Ten Year Return (99.92) | All Time Return (99.92) |
Last Split Factor 1:25 | Last Split Date 2024-08-20 |
1 | Avantor Strengthens Partnership with National Institute for Bioprocessing Research and Training to Address Critical Biopharma Industry Challenges | 10/23/2024 |
2 | Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 in Australia | 10/29/2024 |
3 | Xeris Biopharma Q3 Earnings Snapshot | 11/08/2024 |
4 | COSCIENS Biopharma reports Q3 results | 11/12/2024 |
5 | Q3 2024 Theravance Biopharma Inc Earnings Call Transcript | 11/13/2024 |
6 | Theravance Biopharma Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags | 11/14/2024 |
7 | Cue Biopharma GAAP EPS of -0.17 beats by 0.02, revenue of 3.34M beats by 1.82M | 11/15/2024 |
8 | New Report from Clarivate and Healthcare Executive Explores Mainland Chinas Biopharma Revolution and Increasing Global Influence | 11/18/2024 |
9 | Alpha Biopharma received NMPA approval for Zorifertinib Tablets , the worlds first EGFR-TKI for lung cancer with brain metastases. | 11/20/2024 |
| Begin Period Cash Flow | 20 M |
Redhill |
Redhill Biopharma Relative Risk vs. Return Landscape
If you would invest 843.00 in Redhill Biopharma on August 24, 2024 and sell it today you would lose (169.00) from holding Redhill Biopharma or give up 20.05% of portfolio value over 90 days. Redhill Biopharma is currently does not generate positive expected returns and assumes 4.8143% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Redhill, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Redhill Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Redhill Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Redhill Biopharma, and traders can use it to determine the average amount a Redhill Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0504
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RDHL |
Estimated Market Risk
| 4.81 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.24 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Redhill Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Redhill Biopharma by adding Redhill Biopharma to a well-diversified portfolio.
Redhill Biopharma Fundamentals Growth
Redhill Stock prices reflect investors' perceptions of the future prospects and financial health of Redhill Biopharma, and Redhill Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Redhill Stock performance.
| Return On Equity | -17.09 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (3.28) % | ||||
| Current Valuation | 1.48 M | ||||
| Shares Outstanding | 1.28 M | ||||
| Price To Earning | (3.67) X | ||||
| Price To Book | 134.35 X | ||||
| Price To Sales | 2.21 X | ||||
| Revenue | 6.51 M | ||||
| Gross Profit | 45.25 M | ||||
| EBITDA | 26.27 M | ||||
| Net Income | 23.92 M | ||||
| Cash And Equivalents | 28.86 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 1.17 M | ||||
| Debt To Equity | 9.89 % | ||||
| Current Ratio | 0.98 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (35.82 M) | ||||
| Earnings Per Share | (302.63) X | ||||
| Market Capitalization | 8.2 M | ||||
| Total Asset | 23.05 M | ||||
| Retained Earnings | (407.74 M) | ||||
| Working Capital | (3.1 M) | ||||
| Current Asset | 60.51 M | ||||
| Current Liabilities | 5.51 M | ||||
About Redhill Biopharma Performance
By examining Redhill Biopharma's fundamental ratios, stakeholders can obtain critical insights into Redhill Biopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Redhill Biopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 463.14 | 486.29 | |
| Return On Tangible Assets | 1.37 | 1.44 | |
| Return On Capital Employed | 3.32 | 3.49 | |
| Return On Assets | 1.04 | 1.09 | |
| Return On Equity | 11.56 | 12.14 |
Things to note about Redhill Biopharma performance evaluation
Checking the ongoing alerts about Redhill Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Redhill Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Redhill Biopharma generated a negative expected return over the last 90 days | |
| Redhill Biopharma has high historical volatility and very poor performance | |
| Redhill Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Redhill Biopharma currently holds 1.17 M in liabilities with Debt to Equity (D/E) ratio of 9.89, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Redhill Biopharma has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Redhill Biopharma's use of debt, we should always consider it together with its cash and equity. | |
| Redhill Biopharma currently holds about 28.86 M in cash with (35.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Redhill Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Alpha Biopharma received NMPA approval for Zorifertinib Tablets , the worlds first EGFR-TKI for lung cancer with brain metastases. |
- Analyzing Redhill Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Redhill Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Redhill Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Redhill Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Redhill Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Redhill Biopharma's stock. These opinions can provide insight into Redhill Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.